SLC6A9 and pancreatic neoplasm: Here we focus on two transporters with a high need for conformation-specific binders for the screening of small molecule therapeutics, namely the equilibrative nucleoside transporter 1 (ENT1, SLC29A1) that is involved in ischemia and acts as a biomarker in pancreatic cancer (Yang and Leung, 2015), as well as on the glycine transporter 1 (GlyT1, SLC6A9) that plays an important role in diseases of the central and peripheral nervous system (Harvey and Yee, 2013) (Figure 5A, Figure 6A).